for the treatment of generalized anxiety disorder, in a Phase 2 trial conducted in the United States and United Kingdom, and IHL-675A, an oral fixed dose combination of cannabidiol and ...
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...
Computer-assisted cognitive-behavior therapy (CCBT) and mobile mental health applications warrant continued development and ongoing efforts to increase acceptance among patients and clinicians, ...